Corium International - All Time High

Corium International (CORI) is the Barchart Chart of the Day.  The generic drug company has a Trend Spotter buy signal, a Weighted Alpha of 119.71+ and gained 83.10% in the last year.

The Chart of the Day belongs to Corium International (CORI).  I found the stock by sorting today's All Time High list for the stocks with the highest technical buy signals, then used the Flipchart feature to review the charts.  Since the Trend Spotter signaled a buy on 4/29 the stock gained 42.7%.

Corium International, Inc. is a commercial-stage biopharmaceutical company. It is focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage advanced technologies in transdermal and transmucosal delivery systems. Corium has developed six marketed products in the prescription drug and consumer markets: Clonidine Transdermal Delivery System for hypertension, Fentanyl TDS for chronic pain and four Crest Advanced Seal Whitestrips products. The company has two proprietary transdermal technology platforms with applications in multiple drug categories and indications: Corplex(TM) and MicroCor(R). Corium International, Inc. is headquartered in Menlo Park, California. The status of Barchart's Opinion trading systems are listed below.  Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates.  The indicator numbers shown below therefore may not match what you see live on the Barchart.com web site when you read this report Barchart technical indicators: 100% Barchart technical buy signals Trend Spotter buy signal Above its 20, 50 and 100 day moving averages 15 new highs and up 48.67% in the last month Relative Strength Index 78.72% Barchart computes a technical support level at 11.04 Recently traded at 12.89 with a 50 day moving average of 8.52 Fundamental factors: Market Cap $232.92 million Revenue expected to grow 1.70% this year and another 26.60% next year Earnings estimated to increase 14.50% this year and an additional 30.60% next year Wall Street analysts issued 3 strong buy recommendations on the stock The most reliable technical trading strategy for this stock has been the price vs the 100 day moving average.